News

  • YOU ARE AT |
  • Home
  • News
  • Laboratorio Silanes Agreement

International Presence

  • With more than two decades of expertise in the manufacture and distribution of high quality biosimilar products in emerging market countries, a strong portfolio and pipeline of products, significant development and manufacturing capabilities and an established network of distribution partners, we believe we are well positioned to take advantage of opportunities for growth in the global biosimilar therapeutics market

    / More

April 2011

Biosidus inks an agreement with Laboratorio Silanes in the framework of an official Multisectorial Commercial Mission in Mexico DF

Laboratorios Silanes and Biosidus agree on a complementation in research and productive projects.

In the framework of the recent Multisectorial Commercial Mission that took place in Mexico DF, and in presence of the Argentine Ministry of Science, Technology and Productive Innovation, Dr. Lino Barañao, and authorities of the National Counsel of Science and Technology of Mexico (Conacyt), Biosidus subscribed a significant agreement with the Mexican Laboratorios Silanes, aimed at the commercial and technological complementation between the firms.

This agreement involves productive and commercial aspects including mutual licensing of products, and complementation in reciprocal research and development projects based on the technological platform developed by Biosidus in the field of transgenic animals, to manufacture shark derived antibodies, core R&D project conducted by Silanes.

The particular characteristics of shark antibodies make them extremely advantageous to treat several conditions, particularly those involving the gastrointestinal tract. Moreover, it is expected that products obtained from these antibodies shall be highly thermostable, i.e., they may not demand cool chain for their distribution.